Clinical Research on the Aromatase Inhibitor-associated Bone Loss with the Therapy of Nourishing the Kidney in Ostmenopausal Patients with Breast Cancer
【目的】观察补肾法治疗乳腺癌芳香化酶抑制剂相关骨丢失(aromatase inhibitor—associated bone loss, AIBL)的临床疗效,为补肾中药治疗AIBL提供临床方面的依据。
【方法】将38例符合纳入标准的患者随机分为2组。治疗组19例：以补肾法的中药+依西美坦+钙尔奇D600；对照组19例：依西美坦+钙尔奇D600。观察各组患者入组时及治疗12个月后的腰椎骨密度、雌激素水平,以系统评价补肾法对乳腺癌芳香化酶抑制剂相关骨丢失的的临床效果。并且每3个月复查血分析、肝肾功能、相关抗原的变化,所有资料输入SPSS 17.0软件包进行统计分析,结果用均数±标准差表示,组间均数比较用t检验。
【结果】入组38例病人,因治疗组1人出现对侧乳腺癌剔除,实际入组37例,其中治疗组18例,对照组19例。治疗前两组骨密度及雌二醇基线值比较差异无显著性(P>0.05)；经过12个月的治疗,各组骨密度治疗前后变化均有统计学意义(P<0.05),两组治疗后的骨密度变化亦有统计学意义(P<0.05),治疗组骨密度百分比升高0.069%,对照组骨密度百分比下降0.023%,二者的差异有统计学...
【英文摘要】
Objectives
Exploring the efficency of Traditional Chinese Medicine based on the Aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer, so as to provide clinical evidence for the clinical practice.
Methods
38 cases met the inclusion criteria were randomly divided into 2 groups. Treatment group, of 19 cases:the traditional Chinese medicine nourishing the kidney+exemestane+calcium carbonate D600; control group of 19 cases:Exemestane+calcium carbonate D600. Observed ...
| 
点击下列相关研究机构和相关文献作者，可以直接查到这些机构和作者被《中国知识资源总库》收录的其它文献，使您全面了解该机构和该作者的研究动态和历史。
